Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence

Farr, T D; Wegener, S

Abstract: Despite promising results in preclinical stroke research, translation of experimental data into clinical therapy has been difficult. One reason is the heterogeneity of the disease with outcomes ranging from complete recovery to continued decline. A successful treatment in one situation may be ineffective, or even harmful, in another. To overcome this, treatment must be tailored according to the individual based on identification of the risk of damage and estimation of potential recovery. Neuroimaging, particularly magnetic resonance imaging (MRI), could be the tool for a rapid comprehensive assessment in acute stroke with the potential to guide treatment decisions for a better clinical outcome. This review describes current MRI techniques used to characterize stroke in a preclinical research setting, as well as in the clinic. Furthermore, we will discuss current developments and the future potential of neuroimaging for stroke outcome prediction.

DOI: https://doi.org/10.1038/jcbfm.2010.5
The use of magnetic resonance imaging to predict outcome following stroke: a review of experimental and clinical evidence

Tracy D. Farr¹, Susanne Wegener²

¹ In-vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research, Cologne, Germany
² Department of Neurology, University Hospital Zurich, Switzerland

Short title: MRI for stroke outcome prediction, a clinical and experimental perspective.

Acknowledgment: This work was supported by grants from the StemStroke EU-FP6 program (LSHB-CT-2006-037526), Alexander von Humboldt Research Fellowship (to TDF), the European Commission (Marie-Curie Outgoing International Fellowship), the Department of Neurology, University Hospital Zurich, Switzerland and by the NCCR “Neural Plasticity and Repair” of the Swiss National Science Foundation (to SW).

Address correspondence to:

Susanne Wegener, MD
Department of Neurology
University Hospital Zurich
Frauenklinikstrasse 26
8091 Zurich, Switzerland
Phone: +41 44 255 1111
Fax: +41 44 255 4507
Email: Susanne.Wegener@usz.ch
**Abstract**

Despite promising results in pre-clinical stroke research, translation of experimental data into clinical therapy has been difficult. One reason is the heterogeneity of the disease with outcomes ranging from complete recovery to continued decline. A successful treatment in one situation may be ineffective, or even harmful, in another. To overcome this, treatment must be tailored according to the individual based on identification of the risk of damage and estimation of potential recovery. Neuroimaging, particularly magnetic resonance imaging (MRI), could be the tool for a rapid comprehensive assessment in acute stroke with the potential to guide treatment decisions for a better clinical outcome. This review describes current MRI techniques used to characterize stroke in a pre-clinical research setting, as well as in the clinic. Furthermore, we will discuss current developments and the future potential of neuroimaging for stroke outcome prediction.

**Keywords:** stroke, magnetic resonance imaging, perfusion, diffusion, diffusion tensor imaging, fMRI, outcome prediction
Introduction

Stroke is the third leading cause of death and the leading cause of disability in developed countries globally. The major obstacle to effective acute stroke management is time. It is estimated that fewer than 10% of all stroke patients receive the only approved treatment, thrombolysis with recombinant tissue plasminogen activator (rtPA) (Cocho et al 2005). There are several reasons for this, the primary of which is that thrombolysis is only approved for use within 3 hours following symptom onset, although recent studies have suggested benefit beyond that from 4.5 (Hacke et al 2008) to as long as 6 hours (Davis et al 2008; Rother et al 2002). Other potential reasons include lack of public awareness, intra-hospital delays, or precaution on account of the increased risk (7%) of intracerebral hemorrhage (ICH) that accompanies rtPA (Bambauer et al 2006; Kleindorfer et al 2004). Additionally, it is controversial whether or not small vessel occlusions (lacunar stroke) respond as well to thrombolysis as territorial strokes (Cocho et al 2006; Hsia et al 2003; Hwang et al 2008; Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience 2005). Nevertheless, when successful, early re-canalization is highly correlated with reduced infarct volume and improved outcome scores (Felberg et al 2002; Uchino et al 2005). Because acute neuroimaging is not consistently performed, it is difficult to estimate the number of patients that exhibit spontaneous re-canalization. Reports vary between 77% in patients with cortical infarcts using computed tomography (CT) and 32% in patients with middle cerebral artery occlusion (MCAO) using magnetic resonance angiography (MRA) (Jorgensen et al 1994; Neumann-Haefelin et al 2004), respectively. Clearly, the
heterogeneity of the patient population makes the decision to treat a difficult one. Therefore, effective neuroimaging strategies are essential to improve the standard of patient care.

While CT is still the most prevalent imaging modality in acute stroke, magnetic resonance imaging (MRI) is starting to measure up. The slightly longer acquisition times required for MRI represent a disadvantage. However, in less than 15 minutes several different scans can be obtained that provide much more information regarding different tissue parameters. MRI can identify pre-existing lesions and/or diseases, locate the thrombus, recognize ICH, classify stroke subtype, assess blood supply, and provide information about the approximate time of ischemia onset and the extent of injury. The mission of MRI in acute stroke management is to confirm the clinical diagnosis, provide evidence for pathophysiology and stroke subtype, and to assess the risks and benefits for therapy. In an ideal situation, MRI would provide information that would assist with stratification of patients based on most likely outcome. In the acute clinical setting, important scenarios to differentiate for the clinician are: 1) spontaneous improvement, 2) improvement with therapy and 3) no improvement despite therapy (Figure 1). In this review, we describe the MR imaging techniques currently used as surrogate markers and predictors of outcome in patients and experimental animal models of stroke. Future challenges of MRI-based outcome prediction in stroke will be discussed.
1. Surrogates for outcome assessment

One of the key issues in stroke assessment is how to best choose study endpoints that appropriately indicate outcome. Ideally, the endpoint should reflect the functional impairments caused by the disease and/or their effect on the quality of life. Therefore, the most common endpoints in the clinic are neurological scales. Several neurological scales have been used as surrogates for outcome, among them the modified Rankin Scale (mRS), Glasgow Outcome Scale (GOS), and Barthel Index (BI) (Kasner 2006). The mRS and GOS are used as indicators of functional independence for daily activities; and while both have been shown to be extremely reliable and reproducible (Banks and Marotta 2007), they are not as comprehensive as the BI, which provides a more detailed examination of self care abilities (Sulter et al 1999). However, these measures are usually only performed out to three months because most spontaneous recovery is maximal by 10 weeks (Schiemanck et al 2006). Therefore, these outcome surrogates have not been sufficiently studied long term, despite the fact that the aged brain may be capable of recovery many years after stroke.

In experimental animal research functional outcome surrogates are referred to as behavioral testing. Unfortunately, since most endpoint measures are collected within the first week of the ischemic event it is difficult to identify potential surrogates of functional outcome in the chronic setting. Nevertheless, several approaches have been used to assess functional outcome. A wide range of neurological scores have been developed that attempt to mimic the clinical situation. They range from a simple 0-5 score based primarily on forelimb retraction (Bederson et al 1986) to a slightly more detailed
assessment that includes sensory response to stimuli (Garcia et al 1995). Often this approach is preferred because neurological scores are easy to perform, fast, and require very little equipment or expertise. However, the scores are not particularly sensitive to specific functional impairments and animals exhibit a great deal of recovery. Other tests are designed to maximize the difference between the intact and impaired side of the body, typically, sensory capabilities of the forepaws. These are collectively referred to as asymmetry tests (Barth et al 1990; Schallert et al 2000). Ideally, tests designed to monitor skilled motor function in rodents should provide better comparability to the clinical situation. Challenging tests for skilled motor function exist, for example, skilled reaching for food in trays, on staircases (Montoya et al 1991), or single food items (Whishaw et al 1992). However, the highly labor intensive and interpretive nature of these tests means they are often excluded from the literature.

1.2. Imaging surrogates

1.2.1. Infarct size

MR-assessed final infarct size has been consistently used as an outcome surrogate based on the notion that the size of the insult is correlated with outcome severity. Indeed, a recent meta-analysis of the clinical literature - not part of any randomized clinical trial - reported a correlation between MRI based lesion size and functional outcome parameters (Schiemanck et al 2006). This analysis included studies that employed several different methods to estimate acute lesion size including diffusion and perfusion weighted imaging (DWI and PWI, respectively), as well as $T_2$-weighted
imaging. The $T_2$-weighted volume estimations are typically smaller than the initial DWI or PWI lesion size calculations, and are more reliable for sub-acute and chronic than they are for acute detection. As such, they are often used as a surrogate for final infarct size (Kane et al 2007). DWI and PWI for acute lesion size will be discussed later with respect to their potential to predict final lesion size.

Despite the use of $T_2$-weighted imaging to estimate final infarct size, debate exists regarding whether or not it is the most reliable measure. For example, fluid attenuation inversion recovery (FLAIR) is superior to conventional $T_2$-weighted imaging with regards to lesion conspicuousness in the sub-acute stages (Ricci et al 1999) due to its high sensitivity to very small accumulations of fluid by effectively nulling the signal from the cerebral spinal fluid (CSF). FLAIR is currently included into the routine clinical acquisition scan package. Furthermore, inter-rater agreement using FLAIR has been reported to be better than for $T_2$-weighted imaging (Neumann et al 2009). Manual delineation is still the most common approach to estimate infarct size, despite the significant measurement error (Davis et al 2008), because automated volumetry is confounded by pre-existing disease, individual variances in shape, location, and severity of signal change.

Final infarct size has been used consistently as an outcome surrogate in the experimental animal setting. Infarct size has traditionally been measured with 2, 3, 5-triphenyltetrazolium chloride (TTC), hematoxylin-eosin, or nissl stained brain sections, though the increasing availability of MRI in the experimental research environment has started to produce studies in which $T_2$-weighted imaging has been used to estimate final
Infarct size (Ashioti et al 2007; Farr et al 2007; Palmer et al 2001). Infarct sizes assessed by T2-weighted imaging have been shown to correlate well by some (Palmer et al 2001) and to underestimate histological damage by others (Neumann-Haefelin et al 2000). Unfortunately, infarct size has been the primary, and often only, endpoint measure collected in many experimental stroke studies for quite some time. There are hundreds of potential compounds/drugs that were perceived as potential neuroprotective agents due to their ability to reduce infarct size in rodent models of stroke. However, all have failed to provide any benefits in clinical trials, a comprehensive list of clinical drug trials can be found at the Stroke Trials Registry website of the Internet Stroke Centre (Goldberg). Some of the most popular examples that have made it to Phase III clinical trials without evidence of clinical efficacy include glutamate antagonists (for example, Selfotel: Acute Stroke Studies Involving Selfotel Treatment (ASSIST)) (Davis et al 2000), sodium or calcium channel blockers (for example, Lubeluzole: Lubeluzole in Ischemic Stroke) (Diener et al 2000), or the recently highly publicized free radical scavenger Cerovive: Stroke Acute Ischemic NXY-059 Treatment (SAINT I and II) (Diener et al 2008). It is therefore likely that the criterion of infarct size alone is insufficient to be used as a sole outcome surrogate. Functional connectivity of adjacent brain regions can be affected by a stroke through retrograde degeneration between existing neuronal networks. This is not observable using infarct size estimations, but could be inferred with other imaging modalities.
1.2.2. Diffusion tensor imaging

Anisotropy is the direction dependent diffusion of water, which is faster in the direction of fiber tracts than perpendicular to them. Therefore, diffusion tensor imaging (DTI) was developed to visualize the orientation and properties of white matter (Basser et al. 1994). In principle, DTI could thus be used to detect some degree of physical connectivity between brain regions, which could be employed as an outcome surrogate in the chronic setting. Typically, DTI data are presented as two-dimensional fractional anisotropy (FA) maps. While FA has consistently been shown to decrease post stroke as gray and white matter disintegrate (Buffon et al. 2005), some variability in FA has been observed acutely. Decreases (Morita et al. 2006; Zelaya et al. 1999) and increases (Bhagat et al. 2008; Ozsunar et al. 2004) have been observed, and though the exact mechanism of the increase remains unclear, it is possible that perpendicular diffusion is restricted hyper-acutely. Recovery of FA values 3 years after stroke has been observed in the internal capsule of patients with upper limb impairments subjected to 30 days of motor training (Stinear et al. 2007). If a sufficient number of diffusion directions and gradient strengths are used, DTI data can be reconstructed as 3D maps that are color coded for directional sensitivity and continuous virtual tracts can be traced based on the largest principal diffusivity between voxels (tractography). This strategy has been used to observe changes in the cortico-spinal tract following stroke (Moller et al. 2007) and to correlate DTI signals in certain fiber tracts of the ischemic hemisphere to the likelihood of outcome improvement (Pannek et al. 2009).
In agreement with the clinical reports, FA values also decrease in the ischemic territory of the rat brain over time (depicted in Figure 2). However, some groups have reported increases in FA values near the lesion boundary between 3 and 9 weeks post stroke (van der Zijden et al 2008), which is enhanced with neural progenitor cell treatment (Jiang et al 2006), as well as in the ipsilateral striatum around 21 days post stroke (Granziera et al 2007). The latter two studies also employed ex vivo DTI measurements in order to obtain tractography. Abnormal fiber trajectories were identified that originated in the ischemic and projected to the contralateral striatum in a small subset of animals with subcortical infarcts (Granziera et al 2007), and increased numbers of tracts were observed projecting from the corpus callosum into the injured tissue (Jiang et al 2006).

However, conclusions regarding white matter re-organization must be interpreted cautiously on account of the sensitivity of the measurements and drawbacks with the analysis methods. Additionally, the long acquisition times required for tractography represent a major drawback for in vivo experiments, particularly in the experimental animal setting. Scan times depend on resolution requirements, hardware capabilities, and sequence parameters. For example, to obtain an in plane resolution of 400μm² using 30 diffusion directions and a single gradient strength, acquisition time is estimated to be approximately 30min. This would double with each additional gradient strength and/or average. Time can also be gained with hardware improvements, for example, parallel imaging, which is common in the clinic, and future improvements in analysis strategies could increase the potential of DTI as an imaging surrogate.
1.2.3. Functional MRI

Connectivity between brain regions can also be inferred by measuring brain activity in stroke patients using functional MRI (fMRI). Depending on the kind of functional deficit, individual tasks can be designed to pinpoint where brain activity is impaired and how the ischemic brain has adapted to the injury, which makes fMRI a complementary imaging surrogate to infarct size measurements. With regards to reorganization of motor function after stroke, several general patterns of fMRI activity changes have been observed, reviewed elsewhere (Calautti and Baron 2003; Carey and Seitz 2007; Cramer and Bastings 2000; Grefkes and Fink 2009). Activity significantly increases in motor related and peri-infarct areas, and tasks performed by the impaired hand produce bilateral cortical activation, including regions not activated in intact patients. The heterogeneity of the patient population requires stratification of lesion types in order to identify trends. Subcortical lesions often recruit independently connected cortical regions, whereas patients with cortical lesions exhibit recruitment of peri-infarcted cortices. In general, recruitment of peri-infarct tissue is associated with improved recovery.

The availability of only a few stimulus/response fMRI paradigms in rodents means that this field is relatively unexplored in the pre-clinical research environment. The most well characterized paradigm is the detection of either a cerebral blood flow (CBF) or blood oxygen level dependent (BOLD) response in the primary somatosensory cortex (S1) following electrical stimulation of the forelimbs (Mandeville et al 1998; Silva et al 1999). In general, BOLD and CBV responses to forelimb stimulation are decreased after
MCAO, and become more variable when compared to an intact response in healthy control animals (Butcher et al 2005). However, a few groups have observed changes in the fMRI response that correlate with the clinical literature. Stimulation of the impaired limbs produced activation in the intact sensorimotor cortex, and formerly unresponsive regions in the peri-infarcted tissue (Abo et al 2001; Dijkhuizen et al 2001; Rother et al 2002). Interestingly, when repetitive fMRI sessions were performed in the same animals, three types of responders were characterized: those that retained, those that completely lost, and those that exhibited only a transient loss of the BOLD response that was independent of infarct size measurements (Weber et al 2008). As is the case with DTI, fMRI could offer complimentary information to the standard infarct size estimations and could thus be considered a surrogate.

2. **Outcome predictors**

In contrast to surrogates, which are useful in the chronic setting to assess endpoint measures, outcome predictors are parameters that might be used in the acute setting of stroke to foresee the course of the disease or the potential benefit of treatment. Arguably the most common clinical predictor of outcome is the National Institutes of Health Stroke Scale (NIHSS), which is employed in the acute stroke setting to assess a patient’s neurological symptoms. The NIHSS score has been shown to be highly correlated with differences in lesion size (Warach et al 2000) and is an excellent predictor of outcome determined using the mRS at 3 months (Johnston et al 2009;
Kasner 2006). Ideally, as is the case with surrogates, additional predictors would be extremely useful and in this section we discuss several promising MRI predictors.

2.1. MR angiography

MR angiography (MRA) is used acutely in the clinic for fast and effective diagnosis of acute stroke, primarily by identifying the location of the thrombus (Yu et al 2002) and visualizing recanalization either spontaneously or in response to rtPA (Kimura et al 2009). In terms of its predictive potential, MRA has been used to predict the degree of recanalization, which is highly correlated with outcome. The Thrombolysis In Myocardial Infarction (TIMI) grading system has been applied to assess the degree of the recanalization in patients with MCA occlusions using time of flight (TOF) MRA (Neumann-Haefelin et al 2004). Patients with complete, and even minimal, recanalization exhibited significantly less lesion growth.

In addition to the success of recanalization therapies, MRA can be used to predict the risk of stroke by evaluating the degree of stenosis, and/or discrete changes in vessel walls, such as arteriovenous malformations or vasculitis (Kuker et al 2008), reviewed in (Latchaw et al 2009). While conventional intra-arterial angiography (IAA) is still the gold-standard to evaluate the location and severity of vessel stenosis, the risks of this catheter-based procedure are significant. Imaging methods, such as ultrasound, can be preferred. MRA has been shown to be comparable and even superior to ultrasound for evaluating vessel stenosis (Nonent et al 2004). In addition to TOF-MRA where blood flow is visualized noninvasively with short TR-images, contrast enhanced (CE-MRA) is
also routinely employed. In CE-MRA, a Gadolinium bolus is injected intravenously and filling of the vessel lumen recorded using T1-w images. Disadvantages of TOF MRA when compared to CE-MRA are significantly longer scan times and less sensitivity to low flow, which potentially overestimates the degree of stenosis (Nederkoorn et al 2003). Despite the recent suggestion that there is no greater benefit of CE-MRA (Babiarz et al 2009), a meta analysis has revealed that CE-MRA is slightly superior to TOF (Debrey et al 2008). Another interesting application of MRA in stroke is its use to identify several characteristics of the atherosclerotic build up that could provide indications of plaque vulnerability, reviewed in (Saam et al 2007). For example, TOF was able to delineate the boundaries of the inflammatory fibrous cap rupture in atherosclerotic patients (Mitsumori et al 2003), as well as fresh intra-plaque hemorrhage (Yim et al 2008). Additionally, contrast agent, specifically ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs), have been shown to accumulate inside the macrophages contained in the fibrous cap first in rabbits and then in humans (Kooi et al 2003), which could also enhance predictability of rupture potential.

MRA in the experimental setting can be used in much the same fashion as the clinic, to determine thrombus location and recanalization, only when an embolic model is employed (Hilger et al 2002). However, the resolution is currently lacking to obtain images of smaller arteries or main stem branches, which makes implementation of MRA for examination of endothelial disease difficult. The most common model of MCAO in the rodent is the intraluminal filament technique, and model failure is a potential pitfall of this technique (Dittmar et al 2005). MRA has been used to identify and exclude these
animals earlier (Gerriets et al 2004). While MRA use is limited in the experimental setting, development of new contrast agents for examination of atherosclerotic plaques can be tested easily.

2.2. Relaxometry

The susceptibility effects produced by iron in the blood appear as hypointensities in gradient echo images. Therefore, T2*-weighted images are used to identify ICH and or subarachnoid hemorrhage (SAH). It is generally accepted that CT is more accurate for ICH detection acutely (Warlow et al 2003). However, a recent study found that the two modalities were equivalent and that MRI was even slightly better (Kidwell et al 2004). Indeed, a recent review regarding acute stroke imaging recommendations assessed the quality of articles based on level of evidence (LOE) and suggested that the assumption that CT is more accurate for ICH detection than MR is based on a low LOE (Latchaw et al 2009).

It has also been suggested that T2*-weighted MRI could be used to predict which patients might exhibit secondary ICH (SICH) after an ischemic stroke (Nighoghossian et al 2002). Pre-existing hypointensities in T2*-weighted images are often classified as cerebral microbleeds, and regardless of their age, could represent increased risk of SICH. As mentioned previously, these patients are excluded from rtPA treatment, though the prognosis of SICH is not necessarily poor when compared to the potential impact of the initial ischemic event (Derex et al 2004; von Kummer 2002). Furthermore, recent evidence suggests that in fact these patients should not be excluded from rtPA treatment. The Bleeding Risk Analysis in Stroke by T2*-weighted Imaging before
thrombolysis (BRASIL) study revealed no increased risk of SICH from thrombolysis (Fiehler et al 2007). In a recent study, FLAIR images were able to delineate focal regions of hyperintensity prior to thrombolysis that were highly correlated with increased risk of SICH (Cho et al 2008) and could thus be used as an attractive SICH predictor.

In experimental animal research gradient echo imaging is the most common technique for reliable detection of ICH (Neumann-Haefelin et al 2001). However, reproducibility of images from day to day represents a major problem with this technique due to the difficulties associated with shimming across the small rodent brain. Another application for $T_2^*$-weighted images is the detection of susceptibility agents such as contrast agents. Systemic intravenous administration of USPIOs for phagocytosis by activated blood borne macrophages as a method to image the peripheral inflammatory response after stroke is one such application (Rausch et al 2002; Wiart et al 2007). However, evidence indicates this technique might not be so robust (Desestret et al 2009; Henning et al 2009), and more variability has been observed in the clinic (Cho et al 2007; Nighoghossian et al 2007; Saleh et al 2007). Therefore, albeit offering interesting insights into the post-stroke inflammatory reaction, the current potential of these techniques for stroke outcome prediction is poor.
2.3. Diffusion weighted imaging

Many ischemic lesions are difficult to detect within 3 hours using CT (Roberts et al. 2002), which has caused DWI to become of the mainstay of acute stroke imaging, reviewed in (Latchaw et al. 2009; Masdeu et al. 2006). DWI measures random mobility of water (protons) in tissue. Opposing magnetic field gradients first dephase and then rephase the proton spins. If no net movement has occurred, the signal is attenuated. However, if diffusion is restricted, for example, due to inter-compartmental water shift produced by cytotoxic edema during acute stroke, the corresponding diffusion signal is hyperintense, and the quantitative apparent diffusion coefficient (ADC) values (mm$^2$/sec) decrease. ADC maps more clearly discriminate cytotoxic edema from existing pathological entities produced by the T$_2$-shine through effect that can be observed in the DW-images (Detre et al. 1994). In general, ADC values do not change much until CBF drops below 20mL/100g/min. Subsequently, the most severe ADC reductions are found in the center of the perfusion deficit, indicating that specific ADC values are able to discriminate infarcted or necrotic tissue, and thus predict tissue outcome (Kraemer et al. 2005; Thomalla et al. 2003). When regions of interest (ROIs) were drawn around the initial DWI abnormality (core) and again around the hyperintense T$_2$ region (final infarct size), both regions, as well as the difference between the two (tissue at risk) displayed different ADC values: core- 0.56± 0.11, tissue at risk- 0.71± 0.11, and final infarct- 0.63± 0.11 10$^{-3}$ mm$^2$/sec (Na et al. 2004). The most severe ADC decreases (10$^{-3}$ 0.45- 0.7 10$^{-3}$ mm$^2$/sec) are correlated with low cerebral metabolic rates of oxygen (CMRO$_2$) (0.4- 0.5µmol/100mL/min), which is consistent with irreversible tissue damage (Guadagno et al. 2006). However, ADC values become much
more variable in tissue with CMRO$_2$ levels that could be associated with either penumbra or benign oligemia (Guadagno et al 2006). Furthermore, there have been a few reports where ischemic lesions were undetected with DWI (Lefkowitz et al 1999; Wang et al 1999), or that severe ADC decreases normalized, depending on the duration and severity of ischemia (Rother et al 2002). Therefore, the ADC value of a voxel alone is not always sufficient to predict its fate. Recent automated post-processing methods have tried to overcome this problem by incorporating regional ADC measures and local shape regularity constraints (Rosso et al 2009). DWI estimated lesion size is often used to predict outcome since several studies have observed correlations with functional outcome scales (Barrett et al 2009; Johnston et al 2009), though it should be pointed out that a few studies have failed to find a correlation (Hand et al 2006; Wardlaw et al 2002).

As is the case in the clinic, ADC abnormalities are preferred for estimation of infarct size in animal research, and manual delineation showed a better correlation with TTC sections than threshold based estimations (Bratane et al 2009). Nevertheless, several different thresholds have been used to correlate infarct size with histological measurements. ADC volumes, when expressed as threshold of 77% of control values, were highly correlated with measurements of reduced adenosine tri-phosphate (ATP) and glucose consumption (breakdown of energy metabolism). Volumes determined with a threshold of 86% of control values were correlated with measurements of tissue acidosis 24 hours later (Olah et al 2001). An ADC decrease of 33% when compared to the contralateral side was also highly correlated with hemispheric lesion volume at 3
hours post MCAO (Kazemi et al 2004). Another group employed semi-automated software to delineate the lesion based on a combination of ADC and T2-weighted abnormalities at various time points. Infarct size from hematoxylin-eosin sections was highly correlated with the measurements starting around 16 hours post MCAO (Jacobs et al 2000). If reperfusion occurs, the region of ADC abnormality will return to normal or near normal values, and subsequent expansion in the sub-acute stages is variable (Li et al 2000). The eventual extent of the ADC region by 24 hours is highly correlated with occlusion duration (Neumann-Haefelin et al 2000) and several groups have shown with histology that the signal is not solely confined to the neuronal population (Liu et al 2001; Ringer et al 2001). A recent review on the potential of DWI to accurately predict infarct size in experimental animal research indicated that there were only 13 publications that achieved quality scores sufficient to draw conclusions from. In general, manual delineation of lesion size from DWI was a better indicator of neuronal damage than lesions defined by using quantitative ADC thresholds (Rivers and Wardlaw 2005). This implies that although quantitative ADC maps are crucial to unambiguously diagnose acute ischemic damage, ADC defined thresholds might be too dynamic in the course of the disease, to yield a robust outcome predictor.

### 2.4. Perfusion weighted imaging

Perfusion weighted imaging (PWI) is of particular importance in stroke, since the drop in cerebral blood flow (CBF usually specified in mL/100g/min) is one of the first in the cascade of events that ultimately result in brain damage. The extent, severity and
duration of the misery perfusion are a major determinant of outcome. In addition to confirming the diagnosis of stroke and indicating reperfusion, it has been shown that areas with severely compromised perfusion are more likely to undergo infarction, which makes PWI an interesting outcome prediction parameter (Butcher et al 2003). When time of symptom onset is not certain, a persistent perfusion deficit on PWI can help to stratify patients for therapy. Induced hypertension to avoid a remittance of symptoms due to low perfusion pressure after transient ischemia is also typically guided by PWI.

The most common clinical technique for PWI is dynamic susceptibility contrast (DSC)-bolus tracking, which relies on intravenous administration of a contrast agent. The corresponding signal in the blood vessels, and surrounding parenchyma, is subsequently reduced (Villringer et al 1988) and signal change over time can be used to calculate CBF, cerebral blood volume (CBV), and the average time required for any given particle of tracer to pass through the tissue after an ideal bolus injection, mean transit time (MTT) (Barbier et al 2001; Calamante et al 1999; Ostergaard 2005). Compared to the “gold standard” of positron emission tomography (PET) imaging, DSC derived CBF values have large standard deviations and tend to overestimate the hypoperfused tissue in stroke patients (Zaro-Weber et al 2009). An inherent problem with DSC-methods is that perfusion quantification algorithms rely on determining an arterial input function (AIF), which incorporates the concentration of the tracer over time in a voxel within a major artery, usually the middle cerebral artery. The input into this vessel, however, does not always resemble arterial input into the brain tissue, which can result in large and unsystematic errors (Calamante et al 2002). In a recent
comparison of different post-processing algorithms and ten different parameters of perfusion derived from bolus tracking it could be shown that a) the choice of the parameter critically determines the ability to predict final infarct size and that b) simple composite parameters such as the Time-To-Peak (TTP) or First-Moment (FM), resembling the arrival time of contrast in the voxel, might be superior to more sophisticated parameters that involve deconvolution of the AIF. A prolongation of FM of 3.5 seconds predicted infarction with a 75% sensitivity and 78% specificity (Christensen et al 2009). Notably, MRI prediction was better in patients without reperfusion, indicating that, probably due to inter-individual variance, perfusion thresholds might be even more difficult to determine on the verge of recanalization. In a different study, DSC-perfusion maps were predictive of favorable clinical outcome to rtPA treatment when increasing the threshold for the delay of the TTP residue function (Tmax) (Olivot et al 2009).

More recently, a non-invasive alternative has become popular in pre-clinical research, arterial spin labeling (ASL) (Detre et al 1994; Williams et al 1992). Pulsed ASL produces contrast by non-selectively, and then selectively, inverting endogenous protons. The resulting signal difference is proportional to the amount of inflowing protons, or CBF. Magnetically labeling blood means this technique is more robust in situations of blood brain barrier (BBB) disruption (Calamante et al 2002). However, quantification can be difficult since assumptions of the quantification algorithms, such as arterial transit time, are difficult to predict in cerebrovascular disease states (Wegener et al 2007). As the method is still fairly young and not yet implemented on many clinical scanners, data are lacking to test the predictive value of ASL-PWI in stroke patients. Regardless, promising
novel methods, such as velocity-selective ASL (tagging blood based on velocity rather than location) (Wong 2007) and arterial territory mapping (Hendrikse et al 2009; van Laar et al 2008) are promising and currently receiving a great deal of attention, as these methods might predict if a certain vessel stenosis is really of relevance for cerebral perfusion in the individual or if collateral blood supply is compensating sufficiently.

In rodent models of stroke, PWI has not been frequently performed, in part because it is hard to implement due to signal-to-noise constraints. In addition to DSC-based techniques, ASL-approaches have been recently introduced to small animal stroke imaging (Leithner et al 2008; Wegener et al 2007). There has been less ambiguity as to the value of PWI in outcome prediction in animal models compared to the clinical setting, which is very likely explained by the homogeneity of vascular occlusions in animal models in contrast to patients (location, duration, clot composition etc.). CBF thresholds have been shown to be useful for infarct size prediction. Voxels with a CBF < 30 mL/100g/min were very likely to be part of the “core” and proceed to infarction despite reperfusion, if ADC values were reduced, too (Shen et al 2003; Shen et al 2004).

2.5. The mismatch concept

Of central importance to stroke outcome is the concept of tissue at risk (Figure 3), which was only touched on in previous sections. Essentially, the region of brain most deprived of CBF (<10mL/100g/min) is thought to be irreversibly damaged and destined for
necrosis (infarct), whereas the surrounding areas retain some degree of CBF (10-22mL/100g/min) and thus represent a combination of tissue that will survive (oligemia) or whose fate is undecided depending on restoration of CBF (penumbra). Many different descriptions and classifications of these regions exist, reviewed elsewhere (Paciaroni et al 2009; Sharp et al 2000). Imaging based identification of these regions is of great importance for outcome prediction and much effort has been made in this respect in the last decade.

Initial observations in patients that the region of DWI was smaller than the region of PWI abnormality lead to the development of the idea that the DWI/PWI ‘mismatch’ could be used to identify tissue at risk (Baird et al 1997; Neumann-Haefelin et al 1999). A DWI/PWI mismatch is illustrated in Figure 4 in a patient with MCAO. A perfusion deficit encompassing 120% of the size of the DWI lesion is generally accepted as a relevant mismatch (Sims et al 2009). If the mismatch resembles a correlate of the real penumbra, two important conclusions should be possible with the detection of a large MRI-defined mismatch: 1) infarct growth if reperfusion is not achieved and 2) a large area of salvageable tissue. The latter suggests that patients with a large mismatch should respond better to thrombolytic treatment with rtPA, which has been shown even beyond the 3 hour time window (Beaulieu et al 1999; Lorenz et al 2006; Ostergaard 2005). However, the selection of patients for thrombolysis based on an MRI-defined mismatch is controversial (Fiebach and Schellinger 2009; Schabitz 2009). Although two phase II trials (DEFUSE and EPITHET) have indicated that patients with a mismatch might respond better to thrombolytic therapy, the DIAS-2 study did not show any benefit
in patients selected for thrombolysis based on the existence of a mismatch (Albers et al 2006; Davis et al 2008; Donnan et al 2009; Hacke et al 2009). Of note, the mismatch in DIAS-2 was defined as a PWI lesion volume > 20% of the DWI lesion volume by visual inspection at each participating stroke center. In DEFUSE and EPITHET, the mismatch (PWI/ DWI lesion volume > 1.2 and PWI – DWI lesion volume ≥ 10ml) was determined by volumetric analysis at a later time point and did not influence stratification of patients into treatment groups. Although a systematic review ascertained that there is insufficient evidence to either provide or withhold thrombolytic treatment based on identification of a mismatch region (Kane et al 2007), this is expected to change with implementation of standardized, quantitative MRI analysis tools for “ad hoc”-calculation of the mismatch before treatment.

As was clear from the previous section, there are many different methods in which to quantify CBF and the choice of which also impacts estimation of the mismatch region. As such, there is no consensus regarding the best method to define the mismatch, which represents a problem regarding translation of findings between studies (Bandera et al 2006). Recent advancements in techniques to estimate metabolic activity such as MRI-based assessment of CMRO2 are expected to contribute to this (Xu et al 2009), as well as combined machines such as MR/PET (Beyer and Pichler 2009). With this technology it would be possible to perform simultaneous measurements, such as the oxygen extraction fraction (OEF) with PET together with DWI/PWI mismatch to achieve a more precise estimate of the penumbra. Although good agreement has been shown between the relative distributions of the MRI-derived mismatch and the PET-derived penumbra, the mismatch is still prone to errors (Takasawa et al 2008). Reasons include
technical challenges regarding quantification of perfusion weighted MRI, the fact that
the lesion on DWI might recover and that areas with benign oligemia are included into
the MRI-defined mismatch definitions (Guadagno et al 2004; Heiss et al 2004; Sobesky
et al 2004; Sobesky et al 2005). In a study where PET was conducted roughly one hour
after MRI assessment of CBF (using the DSC-Bolus tracking technique) in patients with
acute ischemic stroke, a CBF threshold of < 20ml/100g/min was found to best estimate
hypoperfusion within the PET-derived penumbra (Zaro-Weber et al 2009). The
considerable inter-individual variance, the influence of vessel pathology, and the value
of graded CBF-ranges (e.g. 12-20 ml/100g/min) for penumbra selection are areas of
ongoing research in this field.

The concept of the mismatch has not been so extensively studied in animal stroke
research. Mismatch regions have been reported in the acute stages of permanent
MCAO, and in accordance with early clinical reports, the region of ADC abnormality
gradually expands to encompass the region of perfusion deficit within the first 3 hours
(Bardutzky et al 2007; Henninger et al 2006; Meng et al 2004). However, once CBF is
restored in transient models, both DWI and PWI regions of abnormality are diminished
and subsequent expansion is variable. In one study, core pixels were defined by a CBF
decrease of more than 87% and an ADC decrease of more than 30%, whereas
mismatch pixels were defined by a CBF decrease below and an ADC value above the
defined thresholds (Bardutzky et al 2007). Subsequent pixel fate was highly dependent
on the duration of the MCAO. Durations of 35, 60, and 95 minutes resulted in recovery
of 46, 28, and 9% of the core pixels, respectively, whereas 85% of all mismatch pixels
recovered regardless of occlusion duration. Again, quantification of these regions is highly dependent on the choices for thresholds, this can be further complicated by partial volume effects, which are present more frequently in high resolution images (Ren et al 2004). Additionally, differences in the evolution of the mismatch region have also been reported to differ with experimental model (Henninger et al 2006) and animal strain (Bardutzky et al 2005), which are important considerations. As is the case with the clinic, alternative strategies may provide a more balanced perspective. For example, pH-weighted MRI applied to a DWI/PWI mismatch data set was able to identify regions that correspond to penumbra and benign oligemia (Sun et al 2007). Combined PET/MRI (Judenhofer et al 2008) and MRI/SPECT machines are increasingly used and also expected to make a contribution to a better characterization of the tissue at risk and tissue destined to undergo infarction in animal research.

**Outlook**

MRI can assist to predict the functional outcome of stroke patients. Several MRI parameters are correlated with a favorable outcome: 1) early recanalization on MRA, 2) small tissue defect on DWI, 3) small size and degree of perfusion deficit on PWI, 4) restored functional activity in peri-infarct areas on fMRI and intact descending pathways on DTI. However, the decision regarding whether or not a patient should receive thrombolysis solely based on MRI assessment remains problematic and controversial.
Many of the problems and open questions of stroke outcome prediction are similar in experimental animal research and in the clinic. However, the quality of pre-clinical research must be improved in order to make a better impact in the clinic. Low statistical power, flawed statistical interpretation, reproducibility, blinding, randomization, quality control, and publication bias have all been suggested to contribute to the lack of effective translational stroke research (Dirnagl 2006). Once pre-clinical knowledge is ready to be applied to patients, multicenter studies are the only way to reach sufficient numbers for relevant conclusions, at which point standardization of MR acquisition and analysis strategies are essential. In addition, more long-term measures are required for ultimate evaluation of attempts at outcome prediction. Nevertheless, the field of experimental neuroimaging with MRI is rapidly expanding. Improvements in hardware and sequences that decrease scan time while maintaining resolution will continue to impact the field. Post processing strategies must also evolve to these increasingly complicated data sets. It also seems clear that multi-modal imaging strategies are necessary in order to develop more detailed patient profiles that can be used to predict outcome. MRI prediction of stroke outcome and treatment response will remain an area of exciting research and a realistic goal for the next decade.
**Figure Captions**

Figure 1: MRI-guided stroke therapy. Three clinical scenarios are indicated in this diagram 1) spontaneous improvement, 2) improvement in response to therapy, and 3) no spontaneous improvement or response to therapy. Only in scenario 2) is therapy really effective, while side effects could worsen outcome in 1) and 3).

Figure 2: Changes in DTI in rats following transient MCAO. FA maps at different time points (days D0-D14) averaged from 8 animals, overlaid onto averaged ADC maps. In the acute stages, there is a local FA increase (arrow on d0) in the ischemic territory. Subsequently, anisotropy decreases and fiber tracts degenerate ipsilateral to the lesion (arrow in d14). Corresponding ADC increases with tissue necrosis and liquification.

Figure 3: The penumbra. CBF thresholds have been used to identify tissue that will exhibit irreversible damage (infarct core <10mL/100g/min) and that could be salvageable (penumbra 10-17mL/100g/min) because some degree of metabolic activity remains. Theoretically, if CBF is not restored the core will gradually expand in the sub-acute stages as penumbral tissue dies. The MRI defined DWI/PWI “mismatch” is the area of potential lesion growth. It is defined by the initial area of perfusion deficit (which usually includes the area of oligemia) minus the initial area with severe diffusion deficit (core). Growth of the core region can be variable (continuous or dashed arrows) depending on the defined DWI and CBF thresholds, reperfusion, and individual tissue resistance.
Figure 4: Identification of the DWI/PWI mismatch. DW-images (left) and PW-images (middle) in an 80 year old patient at eight hours after the onset of acute aphasia, left-sided sensorimotor hemiparesis and hemianopsia. Note: the small hyperintense lesion in DWI compared to the large area of hypoperfusion in PWI. MR angiography (MRA) reveals proximal occlusion of the left middle cerebral artery. Kindly provided by J. Fiebach, Department of Neurology, Charité Universitätsmedizin Berlin.
References


6-hour stroke patients using voxel-based receiver operating characteristics analysis. Stroke 40:2055-61


hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. *Stroke* 31:2543-51


artery occlusion: a comparison between the suture and the macrosphere model using magnetic resonance angiography. *Stroke* 35:2372-7


